利用苏格兰国家数据集评估呼吸道合胞病毒母体疫苗接种的益处 (BORLAND)
基于苏格兰国家数据集的呼吸道合胞病毒母体疫苗接种效益评估
This study will use a retrospective cohort design and will be conducted within routinely collected national healthcare and statutory demographic datasets held by PHS and National Records of Scotland (NRS). As such, there will be no active enrollment of study participants, no direct contact with study participants, no collection of any primary data outside of the standard of care (SOC), and no requirement for informed consent.
This study design was chosen due to several advantages, over other possible designs, including the ability to evaluate incidence of study outcomes in exposed and unexposed infants, ability to follow infants longitudinally to evaluate study outcomes through 12 months of age, and ability to evaluate all-cause outcomes.
Study endpoints, including RSV-associated LRTD hospitalization and RSV-associated hospitalization, among infants born to ABRYSVO-vaccinated mothers (exposed group) will be compared with those among infants born to ABRYSVO-unvaccinated mothers (comparison group) initially from birth through 6 months of age, with later analysis from birth through 12 months as the infants reach this age threshold and their data become available.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Pfizer CT.gov Call Center
- 电话号码:1-800-718-1021
- 邮箱:ClinicalTrials.gov_Inquiries@pfizer.com
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
This will be a whole population birth cohort study of all live-born infants born in Scotland during the study period. In Scotland, all infants are assigned a unique identifier, the Community Health Index (CHI) at birth. CHI is a common identifier across all National Health Service (NHS) healthcare encounters and allows linkage of all healthcare data to statutory datasets such as death records. The patient population will include all live-born infants born in Scotland over an 18-month accrual period, from 1st September 2024 - 28th February 2026 (or end of RSV season) and their mothers (approximately 69,000 mother-infant pairs). Selection criteria for the population were based on the time period of the RSV season in Scotland and the earliest gestational age eligible for ABRYSVO vaccination, per the MHRA. All infants will be followed for 12 months after birth; thus, the last outcome assessment will be approximately 28th February 2027.
描述
Infants must meet all inclusion criteria to be eligible for inclusion in the study:
- Live birth in Scotland from 1st September 2024 to 28th February 2026
- Gestational age at birth ≥28(0/7) weeks of gestation (earliest gestational age eligible for ABRYSVO vaccination)
Infants meeting any of the following criteria will not be included in the study:
- Born to a mother who received any licensed or investigational RSV vaccine other than ABRYSVO at any time during pregnancy
- Meets UK national guidelines for monoclonal antibody receipt
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:RETROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Exposed
Infants whose mother received ABRYSVO vaccine during pregnancy 14 days or more before delivery |
ABRYSVO |
|
Unexposed
Infants born to mothers who did not receive ABRYSVO during pregnancy will be considered unexposed |
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
出生后180天内发生经PCR确诊的RSV相关下呼吸道疾病住院(首次发作)
大体时间:出生后≤180天
|
出生后≤180天
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
出生后180天内发生的PCR确诊RSV相关住院(首次发作)
大体时间:出生后≤180天
|
出生后≤180天
|
|
出生后180天内发生的PCR确诊RSV相关下呼吸道疾病住院(首次发作),按足月/早产状态和接种疫苗时的胎龄分层
大体时间:出生后≤180天
|
出生后≤180天
|
|
经PCR确诊的RSV相关住院(首次发作),发生在出生后≤180天内,按分娩时的足月/早产状态和接种疫苗时的胎龄进行分层
大体时间:出生后≤180天
|
出生后≤180天
|
|
出生后≤360天内发生经PCR确诊的RSV相关下呼吸道感染住院(首次发作)(按累积和离散年龄区间统计)
大体时间:出生后≤360天
|
出生后≤360天
|
|
PCR确诊的RSV相关住院(首次发作),发生在出生后≤360天内(按累积和离散年龄区间划分)
大体时间:出生后≤360天
|
出生后≤360天
|
|
出生后≤360天内发生的下呼吸道感染住院(任何原因)(RSV流行季节首次发作)(累计及按年龄段划分)
大体时间:出生后≤360天
|
出生后≤360天
|
|
出生后360天内发生的ARI住院(任何原因)(RSV季节期间首次发作)(累计及按年龄区间)
大体时间:出生后 ≤360 天
|
出生后 ≤360 天
|
其他结果措施
结果测量 |
大体时间 |
|---|---|
|
PCR确诊RSV相关住院情况按以下因素分层:分娩时胎龄(GA)、接种疫苗时胎龄、接种至分娩时间间隔、是否与其他母体疫苗同时接种、母乳喂养状况及婴儿贫困指数
大体时间:出生后≤360天
|
出生后≤360天
|
|
婴儿及住院特征(例如:婴儿住院时的年龄、住院天数、护理级别、疾病严重程度、死亡情况)——针对出生后≤360天内因呼吸道合胞病毒(RSV)相关住院的婴儿及其母亲ABYRSVO疫苗接种状况
大体时间:出生后≤360天
|
出生后≤360天
|
|
按性别、出生胎龄、低出生体重、贫困指数、种族、疫苗接种至分娩间隔时间以及母体疾病状态分组的,接种ABRYSVO疫苗母亲所生婴儿突破性RSV感染的相对风险
大体时间:出生后≤360天
|
出生后≤360天
|
合作者和调查者
赞助
调查人员
- 研究主任:Pfizer CT.gov Call Center、Pfizer
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.